|Slideshows|May 13, 2019

7 Ways to Treat Tardive Dyskinesia

Once thought untreatable, we now have two FDA-approved medications for TD and a handful of off-label options. More in this research update.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

ByLeah Kuntz

May 18th 2026

AI Screening Tool for Tardive Dyskinesia Identifies Disorder and Prompts Clinical Evaluation

ByJessica Walters

April 28th 2026

First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

ByLeah Kuntz

March 27th 2026

Phase 2 Study Initiated for NBI-1065890 to Treat Tardive Dyskinesia

ByJessica Walters

January 26th 2026

New Head-to-Head Data Shows Higher VMAT2 Target Occupancy for Ingrezza Compared With Austedo XR

ByLeah Kuntz

January 15th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

7 Ways to Treat Tardive Dyskinesia

Related Content

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

AI Screening Tool for Tardive Dyskinesia Identifies Disorder and Prompts Clinical Evaluation

First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

Phase 2 Study Initiated for NBI-1065890 to Treat Tardive Dyskinesia

New Head-to-Head Data Shows Higher VMAT2 Target Occupancy for Ingrezza Compared With Austedo XR

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

Monoamines: A Full House

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings